Last $32.77 USD
Change Today +0.035 / 0.11%
Volume 3.1K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 9:32 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Open
$32.84
Previous Close
$32.36
Day High
$32.95
Day Low
$32.77
52 Week High
03/19/14 - $39.95
52 Week Low
01/7/14 - $27.51
Market Cap
1.4B
Average Volume 10 Days
390.4K
EPS TTM
$0.46
Shares Outstanding
41.7M
EX-Date
--
P/E TM
70.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACORDA THERAPEUTICS INC (ACOR)

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company’s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.

421 Employees
Last Reported Date: 03/3/14
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $720.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $193.9K
Chief of Business Operations
Total Annual Compensation: $312.7K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $517.7K
Chief Medical Officer
Total Annual Compensation: $418.5K
Compensation as of Fiscal Year 2013.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Sales Guidance for the Year 2014; Plans to Begin Phase III Clinical Trial

Acorda Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter the company reported GAAP net income of $4.7 million for the second quarter of 2014 or $0.11 per diluted share against $3.9 million, or $0.09 per diluted share a year ago. Non-GAAP net income was $17.7 million, or $0.42 per diluted share. Non-GAAP net income in the same quarter of 2013 was $14.1 million, or $0.34 per diluted share. Total revenues were $97.1 million against $87.1 million reported last year. Operating income was $11 million against $8.7 million a year ago period. Income before income taxes was $10.7 million against $8.2 million reported last year. Net revenue was $87.4 million compared to $77.8 million for the same quarter in 2013. For the six months, the company reported total revenues of $177.6 million compared to $158.9 million reported in the same period a year ago. Net income was $5.4 million or $0.13 per diluted share against net income of $2.8 million or $0.07 per diluted share reported a year ago. Non-GAAP net income was $26.5 million or $0.63 per diluted share against net income of $15.4 million or $0.37 per diluted share reported last year. Operating income was $14.4 million against $6.2 million reported last year. Income before income taxes was $14.2 million against $5.2 million reported a year ago. The company reiterates 2014 AMPYRA net sales guidance of $328 million to $335 million. The company announced that it expects to begin a Phase III clinical trial by the end of the year, studying the use of dalfampridine, which is the active ingredient in AMPYRA, twice-daily to improve walking in people who've experienced a stroke in the past. This formulation was used in its proof-of-concept study, for which the company announced positive results in 2013. But it is working on a new once-daily or QD formulation, which depending on when the company complete development, could potentially be introduced into the Phase III program later.

Acorda Therapeutics, Inc., Q2 2014 Earnings Call, Jul 31, 2014

Acorda Therapeutics, Inc., Q2 2014 Earnings Call, Jul 31, 2014

Acorda Therapeutics, Inc. to Initiate Phase 3 Clinical Trial, Studying Use of Dalfampridine Administered Twice Daily to Improve Walking in People Who Experienced Stroke

Acorda Therapeutics, Inc. expects to initiate a Phase 3 clinical trial by the end of this year studying the use of dalfampridine administered twice daily (BID) to improve walking in people who have experienced a stroke. The company has been exploring a once-daily (QD) formulation of dalfampridine for use in the post-stroke clinical program. Based on the results of an in-vitro alcohol dose dumping study and a subsequent fed-fasted study, the company has determined that the current QD formulation is not practical for further testing. The company is working with external partners to develop a new QD formulation that could be included in future post-stroke clinical trials.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $32.78 USD +0.05

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $341.64 USD -1.35
Durect Corp $1.58 USD 0.00
Novartis AG SFr.82.50 CHF +0.30
Teva Pharmaceutical Industries Ltd $52.42 USD +0.20
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 71.6x
Price/Sales 3.7x
Price/Book 2.7x
Price/Cash Flow 70.9x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit www.acorda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.